

A UNIQUE FORMULATION¹

POLYNUCLEOTIDE (PN) 20MG/ML
DNA Optimizing Technology (DOT™)²


Improves the appearance of uneven skin tone
Improves the appearance of skin irregularities
Minimizes pore appearance
Refines the appearance of visible scars



FULL FACE - NECK - DECOLLETE - HANDS

●●●● VISCOSITY


PACKAGING 2ml x 2 syringes
NEEDLE 33G 4mm



PERIOCCULAR

○○●● VISCOSITY


PACKAGING 1ml x 1 syringe
NEEDLE 34G 4mm



ATROPHIC SCARS

●●●● VISCOSITY

PACKAGING 1ml x 1 syringe
NEEDLE 30G 8mm



PROTOCOL AND USE

1 cycle: 3-4 sessions at 3-4 weeks (*maximum*)
Depth: intradermal
Technique: serial/multi-puncture injections (papulas)
Injection volume : 0.02 - 0.05 ml (0.5~2 cm intervals)





Illustration for application schedule only. This diagram does not represent clinical efficacy or treatment outcomes.







Maintenance:

For REJURAN® I and S: once every 3 months
For REJURAN® Healer: 1 additional session at 6 months, 1 cycle per 12 months

- This study included 5 Korean women, 2 in their 30s and 3 in their 40s.
- Protocol: 4 injections session at 2-week intervals; were performed intradermally with 33G needle.
- Total of 1 mL per **cheek** injected with ~0.05 mL per injection point.

OBSERVED CHANGES IN SKIN APPEARANCE



- Improvements in the appearance of pores and skin texture were more noticeable in subjects in their 30s.
- Improvements in the appearance of skin tone and overall skin appearance were more noticeable in subjects in their 40s.

SKIN APPEARANCE RESULTS



BEFORE



AFTER

@Copyright: Vira Melnyk



BEFORE



AFTER

@Copyright: Valeria Zavorin

1. [DB00(00)] REJURAN information for use.

2. Patent No. : 10-0986603

3. Park.K and al. Long-chain polynucleotide filler for skin rejuvenation: efficacy and complications in five patients. Dermatologic Therapy. 2016 Jan-Feb;29(1):37-40. doi: 10.1111/dth.12299

Rejuran®, Rejuran® i, and Rejuran® s are Class III medical devices, regulated health products bearing the CE marking (CE 2265). Rejuran®, Rejuran® i, and Rejuran® s are intended to promote tissue restoration and reconstruction, as well as the improvement of physical appearance on the face, neck, décolleté, and hands. These products are only to be administered by appropriately trained healthcare professionals who are qualified or accredited in accordance with national law. Consult the IFU before injection. Any serious side effects occurring in relation to the product should be reported without delay to Laboratoires VIVACY (customer.complaint@vivacy.fr) and to the national health authority of the country in which the patient is established. Manufacturer: PharmaResearch 77-19, Gwahakdanji-ro, Gangneung-si, Gangwon-do, Korea. MK1357 vA (12.2025)